Other Clinical Trial - Gender Differences in Pediatric Hematopoietic Stem

Status Completed

Clinical Trial Summary

Gender medicine considers the way in which gender, male or female, affects the development and impact of diseases and the response to therapies. It can be said that it is a new transversal dimension of medicine, which evaluates the gender differences in the physiology, pathophysiology and clinic of many diseases and thus sets itself the goal of reaching optimal therapeutic decisions both in men and women based on proven scientific evidence.

Although knowledge of gender medicine has increased significantly in recent years, a gender approach has not been much developed in pediatrics. In the field of bone marrow transplants, hematopoietic stem cell transplantation is known to be the most effective consolidation therapy in some high-risk hematology malignancies such as acute lymphoblastic leukemia and acute myeloid leukemia, and represents one of the potential treatment for patients suffering from solid tumors and genetic hematological, metabolic diseases and primary immunodeficiencies. Huge progress has been made in high resolution donor typing, choice of conditioning regimens, manipulation of hematopoietic stem cells (HSC) and prevention of serious infections in recent years, which have significantly improved the survival rate of patients undergoing to this procedure.

International literature regarding the response and outcomes from hematopoietic cell transplantation in a gender perspective is completely absent, for these reasons this pilot study was born from the need to understand from a broader perspective and in order to better understand how the gender may or not influence the outcome of transplantation in pediatric patients.

This retrospective analysis of the data will concern all patients who underwent allogeneic or autologous bone marrow transplant. The data will be collected from clinical records and from Regional electronic databases. All data will be collected anonymously and an identification code will be assigned to each case.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hematopoietic Stem Cell Transplantation

Clinical Trial Details

NCT number	NCT04580576
Study type	Observational
Source	IRCCS Burlo Garofolo
Contact
Status	Completed
Phase
Start date	January 1, 2000
Completion date	October 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00766883` - Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant	Phase 2
Recruiting	`NCT06148610` - Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Recruiting	`NCT04690933` - AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
Completed	`NCT02564458` - Fitness in Allogeneic Stem Cell Transplantation	N/A
Recruiting	`NCT02543073` - MSC for Treatment of Interstitial Lung Disease After Allo-HSCT	Phase 1/Phase 2
Not yet recruiting	`NCT01714557` - Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT00701688` - Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Phase 1
Completed	`NCT00023530` - Blood and Marrow Transplant Clinical Research Network	N/A
Recruiting	`NCT04092309` - Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation	N/A
Completed	`NCT00000603` - Cord Blood Stem Cell Transplantation Study (COBLT)	Phase 2
Completed	`NCT02663622` - Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)	Phase 2
Recruiting	`NCT04937634` - Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation	Phase 1
Recruiting	`NCT04203108` - ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis	Phase 4
Withdrawn	`NCT03279133` - Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.	Phase 4
Completed	`NCT03654599` - Effects of Digital Stories Intervention on Psychosocial Well-being	N/A
Completed	`NCT05151406` - Myths and Misconceptions About HSCT in a Limited Resource Region	N/A
Completed	`NCT02241005` - Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci	N/A
Recruiting	`NCT03689465` - PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis	Phase 4
Recruiting	`NCT04868786` - Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplantation	Phase 1
Recruiting	`NCT03010579` - Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Gender Differences in Pediatric Hematopoietic Stem Cell Transplantation (HSCT)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms